Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2020 - Issue 5

Immunohistochemical Expression of Survivin And Ki-67 As Tumor Markers in Breast Cancer Infected Females: A Cross-Sectional Study Download PDF


Afaf Almubark Ali Mohamed, Nazik Elmalaika Obaid, Sara Abdelghani, Abdulaziz Alfahed, Hisham Ali Waggiallah, Lienda Bashier Eltayeb
Cite this article
Mohamed A A A, Obaid N E, Abdelghani S, Alfahed A, Waggiallah H A, Eltayeb L B. Immunohistochemical Expression of Survivin And Ki-67 As Tumor Markers in Breast Cancer Infected Females: A Cross-Sectional Study. Pharmacophore 2020;11(5):41-5
Abstract

Survivin is a part of the apoptosis inhibitor group. It is implicated in the control of the cell division and is commonly distributed in fetal tissues and human tumors, and is never expressed in normal adult tissues. The present study aimed at evaluating Survivin and Ki-67 immunohistochemical expression in breast tumors among the Sudanese females. From a total of 200 archives of formalin-fixed paraffin-embedded (FFPE) tissue sections histologically diagnosed as breast tumor, 75% were malignant and 25% were benign. Immunohistochemical staining for Survivin, Ki-67 was done using the Avidin-Biotin Complex (ABC) method. Data were analyzed using SPSS version 26. Invasive ductal carcinoma was diagnosed in 82.7% of patients, about 44 % of them were grade III. A significant association of Survivin expression was revealed in (36.7%) of malignant samples; while (100%) of the benign tumor samples had a positive expression (P-value = 0.01). Ki-67 had a positive expression in 52% of the malignant cases and was not expressed in benign ones, (P-value = 0.000). Our study indicated that survivin was significantly expressed in all benign and around one-third of the malignant tumors that were correlated with tumor grades. There was also a significant direct proportion association between Ki-67 and tumor grades. 

QR code:

Short Link:
Quick Access

Pharmacophore
ISSN: 2229-5402

By using this website, you agree to our Terms and Conditions, Privacy statement and Cookies policy.

Pharmacophore
© 2020 All rights reserved